Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oriola

0.91 EUR-2.26 %25.9, 17.29
7,763 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-2.26 %
+1.11 %
+3.41 %
-7.14 %
-20.87 %
-22.35 %
-1.52 %
-49.39 %
-50.53 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
168.65M EUR
Turnover
127.09K EUR
P/E (adj.) (26e)
17.84
EV/EBIT (adj.) (26e)
2.7
P/B (26e)
1.77
EV/S (26e)
0.29
Dividend yield-% (26e)
3.3 %
Coverage
Recommendation
Accumulate
Target price
1.00 EUR
Updated
20.07.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 20.07.2026

Latest extensive report

Released: 23.06.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
This is truly a miraculous company, shareholder value has been destroyed for a decade, and now when they should roll up their sleeves and turn things around, the timelines are like “sometime in 2028 or even 2029 we’ll get something done.” I can’t think of another company in my portfolio...
9/17/2026, 2:15 PM
by Hammer
14
@Karo_Hamalainen’s interview featured Oriola’s CFO Mats Danielsson Oriola should have all the prerequisites to deliver good results. In its traditional core business, i.e., pharmaceutical distribution, it shares the Finnish market with Tamro. As the demand for medicines and the need...
9/9/2026, 6:05 AM
by Sijoittaja-alokas
7
The Chairman of the Board of Directors of Kronans Apotek, the Swedish pharmacy company half-owned by Oriola, has changed. According to the Swedish Trade Register, the new Chairman is Lars Gunnar Magnus Håkansson. He is an experienced Swedish business leader and professional board...
9/8/2026, 4:37 PM
by Aktivisti26
7
CEO Katarina was actually chatting in Swedish with our Jesper last week. The themes were largely the same ones we went through in the CFO interview already in the spring after the CMD. The only small takeaway for me from this was Katarina’s comment about Kronans Apotek, where she...
9/17/2026, 11:03 AM
by Rauli_Juva
5
Here is the company report on Oriola from Rauli following the Q2 results Oriola’s Q2 results were slightly below our forecasts. We project that the company will barely reach the earnings improvement it guided for the full year. We estimate that Oriola has the potential for a moderately...
7/20/2026, 4:58 AM
by Sijoittaja-alokas
5
Regarding revenue, it is easier to expect a positive continuation from Kronans, but it could be affected by potential rationalization of the store network. I wouldn’t dare promise a positive trend for earnings development yet, as Kronans’ quarters have been quite volatile. The CEO...
7/17/2026, 10:01 AM
by Rauli_Juva
5
In principle, the hallmarks of an ERP project at a Finnish listed company are as follows: a) The project is never completed b) The project fails, and c) The project costs more than expected. The company itself admits that things have gone pear-shaped: “Lessons learned from the first...
7/17/2026, 9:27 AM
by Trivial
5
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.10
2026

Interim report Q3'26

23.2
2027

Annual report '26

24.3
2027

General meeting '27

Regulatory press release24.09.2026, 11.15

Correction: Oriola Corporation: Notification of a change in shareholding according to Chapter 9, Section 10 of the Securities Market Act

Oriola
Regulatory press release23.09.2026, 16.00

Oriola Corporation: Notification of a change in shareholding according to Chapter 9, Section 10 of the Securities Market Act

Oriola
Regulatory press release18.09.2026, 08.00

Oriola Oyj: Oriola has corrected previously reported financial information

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release17.09.2026, 08.00

Oriola Oyj: Publication schedule for Oriola Corporation's financial reporting in 2027

Oriola
Oriola Q2'26: Træg udvikling
Research20.07.2026, 06.25 by
Rauli Juva

Oriola Q2'26: Træg udvikling

Vi estimerer, at selskabet med nød og næppe vil nå sin udmeldte resultatforbedring for hele året.

Oriola
Oriola Q2'26: Headwinds from higher freight costs6:42
Video17.07.2026, 11.42 by
Rauli Juva

Oriola Q2'26: Headwinds from higher freight costs

Higher freight costs and increased operating expenses weighed on Oriola's earnings in Q2. Meanwhile, associate company Kronans improved its result compared with the corresponding period last year.

Oriola
Oriola, Webcast, Q2'26
Webcast17.07.2026, 09.00

Oriola, Webcast, Q2'26

Oriola
Oriola Q2'26 - kort kommentar: Resultatet var på niveau med sammenligningsperioden
Analyst Comment17.07.2026, 08.05 by
Rauli Juva

Oriola Q2'26 - kort kommentar: Resultatet var på niveau med sammenligningsperioden

Oriolas Q2-regnskab var operationelt en smule svagere end vores forventninger, da selskabets justerede EBITDA forblev på niveau med sammenligningsperioden og var lidt lavere end vores estimater.

Oriola
Regulatory press release17.07.2026, 07.30

Oriola Oyj: Oriola Corporation's Half-Year Report 1 January-30 June 2026

Oriola
Oriola Q2'26 preview: Moderat indtjeningsvækst
Analyst Comment07.07.2026, 07.00 by
Rauli Juva

Oriola Q2'26 preview: Moderat indtjeningsvækst

Vi estimerer, at den justerede EBITDA vil stige en smule til 8,5 MEUR som følge af resultatforbedringen i Products-segmentet.

Oriola
Press release03.07.2026, 08.00

Oriola Oyj: Oriola Corporation to publish its Half-Year Report for January-June 2026 on 17 July 2026

Oriola
Oriola Extensive Report: Patience prescribed
Extensive research23.06.2026, 11.15 by
Rauli Juva

Oriola Extensive Report: Patience prescribed

Oriola's stock looks cheap, but there are clear risks associated with both the balance sheet and operational activities.

Oriola
Regulatory press release12.06.2026, 16.00

Oriola Oyj: Oriola's share buyback programme has been completed

Oriola
Regulatory press release10.06.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 24, 2026

Oriola
Regulatory press release10.06.2026, 14.30

Oriola Oyj: Composition of Oriola Corporation's Shareholders' Nomination Board

Oriola
Regulatory press release05.06.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 23, 2026

Oriola
Regulatory press release05.06.2026, 12.00

CORRECTION: Oriola Corporation's Annual Report 2025 published

Oriola
Regulatory press release29.05.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 22, 2026

Oriola
Regulatory press release22.05.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 21, 2026

Oriola
Regulatory press release15.05.2026, 18.00

Oriola Oyj: Acquisition of own shares during week 20, 2026

Oriola